Rani Therapeutics (RANI) Competitors $0.55 0.00 (-0.69%) As of 03:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RANI vs. PLX, MCRB, OKYO, SPRO, TARA, IOBT, GNLX, AVTX, IMRX, and CNTBShould you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include Protalix BioTherapeutics (PLX), Seres Therapeutics (MCRB), OKYO Pharma (OKYO), Spero Therapeutics (SPRO), Protara Therapeutics (TARA), IO Biotech (IOBT), Genelux (GNLX), Avalo Therapeutics (AVTX), Immuneering (IMRX), and Connect Biopharma (CNTB). These companies are all part of the "pharmaceutical products" industry. Rani Therapeutics vs. Its Competitors Protalix BioTherapeutics Seres Therapeutics OKYO Pharma Spero Therapeutics Protara Therapeutics IO Biotech Genelux Avalo Therapeutics Immuneering Connect Biopharma Protalix BioTherapeutics (NYSE:PLX) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk. Which has more volatility and risk, PLX or RANI? Protalix BioTherapeutics has a beta of -0.21, suggesting that its stock price is 121% less volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500. Do insiders & institutionals hold more shares of PLX or RANI? 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 6.5% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 45.1% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor PLX or RANI? In the previous week, Protalix BioTherapeutics had 8 more articles in the media than Rani Therapeutics. MarketBeat recorded 12 mentions for Protalix BioTherapeutics and 4 mentions for Rani Therapeutics. Protalix BioTherapeutics' average media sentiment score of 1.07 beat Rani Therapeutics' score of 0.58 indicating that Protalix BioTherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PLX or RANI more profitable? Rani Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-21.03% -30.89% -11.74% Rani Therapeutics N/A -1,258.76%-97.97% Do analysts prefer PLX or RANI? Protalix BioTherapeutics currently has a consensus target price of $15.00, suggesting a potential upside of 916.95%. Rani Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 1,240.65%. Given Rani Therapeutics' higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than Protalix BioTherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation and earnings, PLX or RANI? Protalix BioTherapeutics has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$61.95M1.90$8.31M$0.0721.07Rani Therapeutics$1.03M38.17-$30.02M-$0.91-0.60 SummaryRani Therapeutics beats Protalix BioTherapeutics on 8 of the 15 factors compared between the two stocks. Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RANI vs. The Competition Export to ExcelMetricRani TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.31M$3.08B$5.75B$9.66BDividend YieldN/A2.22%3.91%4.09%P/E Ratio-0.6020.4230.8325.12Price / Sales38.17357.77459.36117.70Price / CashN/A41.5625.2228.45Price / Book9.129.599.425.98Net Income-$30.02M-$54.74M$3.26B$265.46M7 Day Performance3.01%2.75%2.09%1.19%1 Month Performance31.62%4.97%3.93%2.85%1 Year Performance-80.46%9.64%29.06%20.47% Rani Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RANIRani Therapeutics3.1611 of 5 stars$0.55-0.7%$7.33+1,233.3%-80.2%$39.53M$1.03M-0.60110News CoverageAnalyst UpgradePLXProtalix BioTherapeutics3.2368 of 5 stars$1.61+4.5%$15.00+831.7%+58.6%$128.17M$59.76M-12.38200Positive NewsAnalyst RevisionMCRBSeres Therapeutics3.2905 of 5 stars$14.53+2.3%$73.67+407.0%+0.5%$124.40M$126.32M-3.16330OKYOOKYO Pharma3.0317 of 5 stars$3.12-4.6%$7.00+124.4%+143.4%$122.99MN/A0.007Gap DownSPROSpero Therapeutics3.9418 of 5 stars$2.20+0.5%$5.00+127.3%+60.5%$122.44M$47.98M-1.72150Earnings ReportTARAProtara Therapeutics2.07 of 5 stars$3.10-1.0%$20.50+561.3%+60.2%$120.76MN/A-1.8030IOBTIO Biotech3.0216 of 5 stars$1.05-42.0%$9.33+788.9%+49.3%$119.24MN/A-0.7030Earnings ReportShort Interest ↑Gap DownHigh Trading VolumeGNLXGenelux1.5302 of 5 stars$3.28+4.1%$17.75+441.2%+75.2%$118.99M$10K-3.8110Positive NewsAVTXAvalo Therapeutics3.5871 of 5 stars$9.01+0.9%$30.00+233.0%-0.1%$117.45M$440K0.0040IMRXImmuneering3.5689 of 5 stars$3.21-1.2%$13.25+312.8%+239.8%$116.95M$320K-1.6460Earnings ReportGap UpCNTBConnect Biopharma3.4519 of 5 stars$2.05-1.0%$7.00+241.5%+73.0%$115.01M$26.03M0.00110Positive NewsShort Interest ↓Analyst Revision Related Companies and Tools Related Companies PLX Alternatives MCRB Alternatives OKYO Alternatives SPRO Alternatives TARA Alternatives IOBT Alternatives GNLX Alternatives AVTX Alternatives IMRX Alternatives CNTB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RANI) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access